Molecular inhibitor of QSOX1 suppresses tumor growth in vivo

Amber L. Fifield, Paul D. Hanavan, Douglas O. Faigel, Eduard Sergienko, Andrey Bobkov, Nathalie Meurice, Joachim L. Petit, Alysia Polito, Thomas R. Caulfield, Erik P. Castle, John A. Copland, Debabrata Mukhopadhyay, Krishnendu Pal, Shamit K. Dutta, Huijun Luo, Thai H. Ho, Douglas F. Lake

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Quiescin sulfhydryl oxidase 1 (QSOX1) is an enzyme overexpressed by many different tumor types. QSOX1 catalyzes the formation of disulfide bonds in proteins. Because short hairpin knockdowns (KD) of QSOX1 have been shown to suppress tumor growth and invasion in vitro and in vivo, we hypothesized that chemical compounds inhibiting QSOX1 enzymatic activity would also suppress tumor growth, invasion, and metastasis. High throughput screening using a QSOX1-based enzymatic assay revealed multiple potential QSOX1 inhibitors. One of the inhibitors, known as “SBI-183,” suppresses tumor cell growth in a Matrigel-based spheroid assay and inhibits invasion in a modified Boyden chamber, but does not affect viability of nonmalignant cells. Oral administration of SBI-183 inhibits tumor growth in 2 independent human xenograft mouse models of renal cell carcinoma. We conclude that SBI-183 warrants further exploration as a useful tool for understanding QSOX1 biology and as a potential novel anticancer agent in tumors that over-express QSOX1.

Original languageEnglish (US)
Pages (from-to)112-122
Number of pages11
JournalMolecular Cancer Therapeutics
Issue number1
StatePublished - 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Molecular inhibitor of QSOX1 suppresses tumor growth in vivo'. Together they form a unique fingerprint.

Cite this